Sign In
Buy XNCR
$20.21
-1.28 (-5.96%)
At Close: Jul 31, 2026
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
04:01pm, Wednesday, 29'th Jul 2026
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR) (“Xencor”), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune dis
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
08:31am, Monday, 20'th Jul 2026
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an
Xencor: Bullish On Their Increasingly In-House Pipeline
04:01pm, Tuesday, 14'th Jul 2026
Xencor, Inc. is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology. The upcoming XmAb819 and XmAb541 dose-selection data will soon clarify
The Biology Came First.
09:00am, Monday, 18'th May 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:40am, Wednesday, 13'th May 2026
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
06:11pm, Wednesday, 06'th May 2026
Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.66 per share a year ago.
Xencor Reports First Quarter 2026 Financial Results
04:01pm, Wednesday, 06'th May 2026
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
06:41pm, Tuesday, 05'th May 2026
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
08:01am, Monday, 04'th May 2026
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re
Xencor (NASDAQ:XNCR) Shares Cross Below 200-Day Moving Average – What’s Next?
04:09am, Wednesday, 01'st Apr 2026
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $13.44 and traded as low as $11.17. Xencor sh
Pre-Market Stock Futures: After a volatile start to the week, futures are trading lower on Tuesday. Markets had plummeted early Monday before the opening bell, only to stage a massive turnaround follo
Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
01:32pm, Wednesday, 11'th Mar 2026
Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of “Moderate Buy” from Analysts
02:26am, Tuesday, 10'th Mar 2026
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten research firms that are presently covering the firm, Marketbeat.com reports. One re
Xencor (NASDAQ:XNCR) Shares Gap Down Following Insider Selling
01:52am, Friday, 06'th Mar 2026
Xencor, Inc. (NASDAQ: XNCR - Get Free Report)'s stock price gapped down before the market opened on Thursday after an insider sold shares in the company. The stock had previously closed at $12.74, but
